Chiasma, Inc. announced the appointment of Anand Varadan as chief commercial officer, effective August 17, 2015. Mr. Varadan brings more than 20 years of commercial experience to Chiasma and will assume responsibility for all commercial activities in the U.S. and Europe around the Company's planned launch of its investigational oral octreotide capsules for the maintenance treatment of adults with acromegaly. Mr. Varadan joins Chiasma from Amgen, where he most recently served as Vice President of Marketing for the U.S. Inflammation and Nephrology Business Unit.